



Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event

Joseph R. Berger¹ · Vineeta Malik² · Stuart Lacey³ · Paul Brunetta⁴ · Patricia B. Lehane³

Published online: 10 April 2018
© The Author(s) 2018

Correction to: Journal of NeuroVirology
<https://doi.org/10.1007/s13365-018-0615-7>

The article “Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event,” written by Joseph R. Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, and Patricia B. Lehane, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 5 March 2018 without open access.

With the author(s)’ decision to opt for Open Choice, the copyright of the article changed on 6 April 2018 to © The Author(s) 2018 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The online version of the original article can be found at <https://doi.org/10.1007/s13365-018-0615-7>

✉ Joseph R. Berger
joseph.berger@uphs.upenn.edu

Vineeta Malik
vineeta.malik@parexel.com

Stuart Lacey
stuart.lacey@roche.com

Paul Brunetta
paul.brunetta@junotherapeutics.com

Patricia B. Lehane
patricia.lehane@roche.com

- ¹ Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Convention Avenue, Room 765, Philadelphia, PA 19104, USA
- ² F. Hoffmann-La Roche, Ltd., Basel, Switzerland
- ³ Roche Products Ltd., Welwyn Garden City, UK
- ⁴ Genentech, Inc, South San Francisco, USA